Memory and naïve B-cell subsets in patients with multiple sclerosis

Neuroscience Letters

Volumn 464, Issue 1, 2009, Pages 74-78

  Niino, Masaaki ^a   Hirotani, Makoto ^a   Miyazaki, Yusei ^a   Sasaki, Hidenao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cluster of differentiation; Interferon; Memory B cell; Multiple sclerosis; Na ve B cell

Indexed keywords

ALPHA4 INTEGRIN; B7 ANTIGEN; CD5 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR3; INTERFERON BETA SERINE; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1;

ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MEMORY CELL; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RELAPSE; REMISSION;

ADULT; ANTIGENS, CD11A; ANTIGENS, CD5; ANTIGENS, CD80; ANTIGENS, CD86; B-LYMPHOCYTE SUBSETS; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTEGRIN ALPHA4; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, CCR5; RECEPTORS, CXCR3;

EID: 69249212155     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.08.010     Document Type: Article

References (22)

1. Alter A., Duddy M., Hebert S., Biernacki K., Prat A., Antel J.P., Yong V.W., Nuttall R.K., Pennington C.J., Edwards D.R., and Bar-Or A. Determinants of human B cell migration across brain endothelial cells. J. Immunol. 170 (2003) 4497-4505
2. Awasthi A., Murugaiyan G., and Kuchroo V.K. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28 (2008) 660-670
3. Bongioanni P., Fioretti C., Vanacore R., Bianchi F., Lombardo F., Ambrogi F., and Meucci G. Lymphocyte subsets in multiple sclerosis. A study with two-colour fluorescence analysis. J. Neurol. Sci. 139 (1996) 71-77
4. Collins M., Ling V., and Carreno B.M. Immortalized human microglial cell line: phenotypic expression. Genome Biol. 6 (2005) 223
5. Duddy M., and Bar-Or A. B-cells in multiple sclerosis. Int. MS. J. 13 (2006) 84-90
6. Duddy M., Niino M., Adatia F., Hebert S., Freedman M., Atkins H., Kim H.J., and Bar-Or A. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J. Immunol. 178 (2007) 6092-6099
7. Fukazawa T., Miyasaka K., Tashiro K., Hamada T., Moriwaka F., Yanagihara T., and Hamada K. MRI findings of multiple sclerosis with acute transverse myelopathy. J. Neurol. Sci. 110 (1992) 27-31
8. Genç K., Dona D.L., and Reder A.T. Increased CD80+ B cells in active multiple sclerosis and reversal by interferon β-1b therapy. J. Clin. Invest. 99 (1997) 2664-2671
9. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., and Smith C.H. HERMES Trial Group, B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 358 (2008) 676-688
10. Jurewicz A., Matysiak M., Tybor K., and Selmaj K. TNF-induced death of adult human oligodendrocytes is mediated by c-jun NH2-terminal kinase-3. Brain 126 (2003) 1358-1370
11. Krumbholz M., Faber H., Steinmeyer F., Hoffmann L.A., Kümpfel T., Pellkofer H., Derfuss T., Ionescu C., Starck M., Hafner C., Hohlfeld R., and Meinl E. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 131 (2008) 1455-1463
12. Kuchroo V.K., Das M.P., Brown J.A., Ranger A.M., Zamvil S.S., Sobel R.A., Weiner H.L., Nabavi N., and Glimcher L.H. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 80 (1995) 707-718
13. Martínez-Cáceres E.M., Espejo C., Brieva L., Pericot I., Tintoré M., Sáez-Torres I., and Montalban X. Expression of chemokine receptors in the different clinical forms of multiple sclerosis. Mult. Scler. 8 (2002) 390-395
14. Neuhaus O., Kieseier B.C., and Hartung H.P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J. Neurol. Sci. 259 (2007) 27-37
15. Niino M., Bodner C., Simard M.L., Alatab S., Gano D., Kim H.J., Trigueiro M., Racicot D., Guérette C., Antel J.P., Fournier A., Grand'Maison F., and Bar-Or A. Natalizumab effects on immune cell responses in multiple sclerosis. Ann. Neurol. 59 (2006) 748-754
16. Pers J.O., Jamin C., Predine-Hug F., Lydyard P., and Youinou P. The role of CD5-expressing B cells in health and disease. Int. J. Mol. Med. 3 (1999) 239-245
17. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
18. Scott T.F., McKolanis J., Rothfus W., and Cottington E. Lymphocyte subsets in relapsing-remitting multiple sclerosis: a longitudinal study of B lymphocytes and T lymphocytes. Neurol. Res. 16 (1994) 385-388
19. Sørensen T.L., Roed H., and Sellebjerg F. Chemokine receptor expression on B cells and effect of interferon-β in multiple sclerosis. J. Neuroimmunol. 122 (2002) 125-131
20. Tourbah A., and Lyon-Caen O. Interferons in multiple sclerosis: ten years' experience. Biochimie 89 (2007) 899-902
21. Trebst C., König F., Ransohoff R., Brück W., and Stangel M. CCR5 expression on macrophages/microglia is associated with early remyelination in multiple sclerosis lesions. Mult. Scler. 14 (2008) 728-733
22. Williams K.C., Ulvestad E., and Hickey W.F. Immunology of multiple sclerosis. Clin. Neurosci. 2 (1994) 229-245